April 12, 2016 – The American Food and Drug Administration (FDA) just approved Venetoclax (Venclexta) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with a …

Venetoclax (Venclexta) for the treatment of patients with chronic lymphocytic leukemia (CLL) Read more »

Tagged with: , , , , , , , , ,

Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O’Brien SM, Liem AK, McIntyre RE, Joshi A, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Lee H, He J, Hu J, Dreiling LK, Friedberg JW Blood 2016 Mar; …

Clinical phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL Read more »

Tagged with: , , , , , , ,

January 20, 2016 – The American Food and Drug Administration (FDA) just approved Ofatumumab (Arzerra)  Injection for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL). Ofatumumab, also …

Ofatumumab (Arzerra) approved for recurrent or progressive chronic lymphocytic leukemia (CLL) Read more »

Tagged with: , , , , , , , , ,

July 28, 2014 – The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor …

The use of Ibrutinib [Imbruvica] expanded to the treatment of chronic lymphocytic leukaemia Read more »

Tagged with: , , ,

July 23, 2014 – The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. Zydelig is being granted traditional approval to treat patients whose chronic lymphocytic leukemia (CLL) has returned (relapsed). …

Idelalisib (Zydelig) for three types of blood cancers approved Read more »

Tagged with: , , , , , , , , ,